NasdaqGM:RLAYBiotechs
Assessing Relay Therapeutics (RLAY) Valuation After New Zovegalisib Breast Cancer Data And Ongoing Phase 3 Trial
Relay Therapeutics (RLAY) is back in focus after presenting new Phase 1/2 ReDiscover data for zovegalisib plus fulvestrant, where a 400 mg twice-daily fed dose showed efficacy and safety in line with earlier higher-dose findings.
See our latest analysis for Relay Therapeutics.
The updated zovegalisib data arrives after a powerful swing in sentiment, with Relay Therapeutics’ 1 year total shareholder return of 223.86% contrasting with a 5 year total shareholder return loss of 71.07%. Its 30 day...